More than one in four biotechs that went public in 2020 are trading below cash, according to a new STAT analysis of data from the financial database provider Sentieo.
The indicator — which means a company has more cash on hand than its overall public valuation — seems like further, glaring evidence that too many biotechs raced to market in 2020, a favorite hypothesis among investors whose life science portfolios have plummeted this year.
“For a company to trade below cash is like the investing equivalent of having a very bad credit score. It is a sign that investors believe you are headed towards trouble and are at a risk of being unable to create any value for your investors,” said investor Brad Loncar.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
